WEST PHARMACEUTICAL SERVICES, INC.
In the published model solve dated 2026-Q2, anchored at $337.47, WEST PHARMACEUTICAL SERVICES, INC. (WST) is priced for today's economics sustained for ~6.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
At $327.94 the price works out to roughly 38x company-wide operating income, a multiple that sits at the very top of the peer distribution and implies operating growth held near the self-funding ceiling for about eight years. The business is the dominant supplier of elastomer components for injectable drugs, and GLP-1 demand has reignited growth. Q1 2026 revenue rose 21% to $845 million, adjusted EPS jumped 47% to $2.13, and management raised full-year guidance. Management returns capital aggr
Is WST overvalued? See what's priced in →
730 institutional managers reported holding WST in 13F filings for the quarter ended 2026-03-31. 75 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 2.3M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
WST has cut its share count 2.7% over the past five years, spending $1.63B on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 16 years straight; the current rate is $0.86 a share annually. Cash returned over the past three years: $164.90M in dividends and $1.20B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at WST over the trailing three years. Absence is a fact about the company, not a signal. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
WST's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -3.7% | +2.7% |
| 2023-10-27 | -10.4% | +9.7% |
| 2024-02-21 | -11.3% | +8.3% |
| 2024-04-26 | -6.6% | -8.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
WST's latest 8-K filings: 2026-07-23 (items 2.02, 7.01, 9.01); 2026-07-14 (items 1.01, 9.01); 2026-06-01 (items 5.02, 7.01, 9.01); 2026-05-11 (items 1.05, 7.01, 9.01); 2026-05-05 (items 5.07, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.